Transdermal delivery of dopaminergic agents

Author:

Abstract
The answer to this question is “Yes, but.” Obviously, the presently marketed DA agonists are far from ideal and do not meet several of the needs of patients with PD. Their symptomatic efficacy is less than that of levodopa; they can induce adverse reactions including nausea, hypotension, somnolence, edema, psychosis, and others; they did not prove to modify the clinical progression of the disease; and they do not improve, and sometimes even exacerbate, some of the most disabling nonmotor PD symptoms such as falls, autonomic dysfunction, or dementia.3 Therefore, we need new agents. But novelty alone is simply inadequate. Novelty must be accompanied by the demonstration that any new agonist will provide some advantage or some innovation compared with the already marketed agents. We are not asking for new “me-too” drugs.